Showing results (121-130 of 150) with videos related to
Sort By:
Pageof 15
JAMA Oncology|September 2, 2021
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical TrialLeora Horn, Ziping Wang, Gang Wu, et al.Translational Lung Cancer Research|March 15, 2021
Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verificationBo Jia, Xinghui Zhao, Di Wu, et al.The Lancet. Respiratory Medicine|May 8, 2023
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trialShun Lu, Lin Wu, Hong Jian, et al.Journal of the National Cancer Center|July 22, 2024
Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomasJia Zhong, Xiaoting Li, Zhijie Wang, et al.The Lancet. Oncology|July 31, 2022
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trialShun Lu, Lin Wu, Hong Jian, et al.Cancer Cell International|December 10, 2020
Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patientsBo Jia, Zhi Dong, Di Wu, et al.Lung Cancer (Amsterdam, Netherlands)|May 6, 2026
SMARCA4-deficient thoracic tumors exhibit an immunosuppressive microenvironment and respond to combined antiangiogenic and immune checkpoint inhibitor therapyPanpan Zhang, Yanbin Kuang, Bo Jia, et al.Journal of the National Cancer Center|July 22, 2024
Erratum to 'Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas' [Journal of the National Cancer Center, 1 (2021), 4: 153-162]Jia Zhong, Xiaoting Li, Zhijie Wang, et al.Nature Medicine|May 16, 2025
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trialCaicun Zhou, Xiaorong Dong, Gongyan Chen, et al.Translational Lung Cancer Research|August 13, 2025
Prognostic significance of micropapillary pattern and risk factors in patients with resected stage I lung adenocarcinoma and possible benefit of adjuvant therapy: a real-world multicenter studyJianjie Li, Yujia Chi, Bo Jia, et al.Pageof 15